GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (FRA:DC8A) » Definitions » Notes Receivable

Durect (FRA:DC8A) Notes Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Durect Notes Receivable?

Durect's Notes Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


Durect Notes Receivable Historical Data

The historical data trend for Durect's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durect Notes Receivable Chart

Durect Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Durect Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Durect Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Durect Notes Receivable Related Terms

Thank you for viewing the detailed overview of Durect's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Durect (FRA:DC8A) Business Description

Traded in Other Exchanges
Address
10260 Bubb Road, Cupertino, CA, USA, 95014
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Durect (FRA:DC8A) Headlines

No Headlines